Applied intelligence in clinical drug development: Potential benefits and emerging concerns

Area of Science:

• Pharmaceutical Sciences
• Biotechnology
• Computational Biology

Background:

• Artificial intelligence (AI) and machine learning (ML) are rapidly advancing, transitioning from theoretical concepts to practical applications.
• The pharmaceutical industry is increasingly investigating AI tools for novel product discovery and clinical development processes.

Purpose of the Study:

• To explore the potential benefits of applying AI in pharmaceutical product discovery and clinical development.
• To identify and discuss emerging concerns and challenges associated with the integration of AI in clinical drug development.

Main Methods:

• Review of current and potential applications of AI in clinical development, including participant enrollment, study optimization, data analysis, and pharmacovigilance.
• Examination of AI's role in outcome prediction, data analysis, real-world data phenotyping, and regulatory submissions.
• Discussion of the scientific validity, technical quality, and ethical considerations for widespread AI adoption.

Main Results:

• AI applications show promise in enhancing efficiency across various stages of clinical development, from participant selection to data analysis and pharmacovigilance.
• Specific AI uses include outcome prediction, anomaly detection, imaging analysis, and pharmacometric modeling for regulatory purposes.
• Challenges remain in balancing AI's benefits against risks, addressing scientific validity, technical quality, and ethical implications.

Conclusions:

• AI and ML technologies present transformative opportunities for pharmaceutical research and development.
• Successful integration requires a thorough evaluation of benefits versus risks, alongside robust scientific and ethical frameworks.
• Addressing challenges in understanding and validating AI applications is crucial for its widespread adoption in clinical drug development.